Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Gabelli Funds"


25 mentions found


Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailKey focus for Berkshire's meeting this year will be succession plans, says Chris MarangiChris Marangi, Co-CIO of Value at Gabelli Funds, discusses Berkshire Hathaway's annual meeting.
Persons: Chris Marangi Chris Marangi Organizations: Funds Locations: Berkshire
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBoeing makes safe aircraft, and the data supports it: Gabelli's Tony BancroftTony Bancroft, portfolio manager at Gabelli Funds, joins 'Power Lunch' to discuss the Boeing whistleblower on Capitol Hill and how it may impact the airline industry.
Persons: Tony Bancroft Tony Bancroft Organizations: Boeing, Gabelli, Capitol
Gold, typically seen as a haven in periods of economic turmoil, especially as a hedge against inflation, has risen sharply in price over the past month, even as the outlook for the economy has improved and inflation, although still elevated, is well below recent highs. The precious metal has set a series of record highs as it surged roughly $300, to $2,350 per troy ounce, since the start of March. The move has been attributed, at least in part, to a burst of gold buying from central banks around the world, including China. But investors said that central bank purchases did not fully explain such a sudden price increase. “It’s perplexing to anybody in the gold market,” said Chris Mancini, a gold portfolio manager at Gabelli Funds.
Persons: , Chris Mancini Organizations: Gabelli Funds Locations: China
Alphabet needs to correct its artificial intelligence flubs and prove its monetization potential if it hopes to renew investors confidence. GOOGL YTD mountain Alphabet shares this year "There's uncertainty around the moat," said Jamie Meyers, an analyst at Laffer Tengler Investments. "It's an opportunity that is meaningfully underestimated by investors given everything that's happened," said Deepwater Asset Management's Gene Munster. Using the pullback as an opportunity Many investors, however, are finding the positive in Alphabet's recent troubles for their portfolios, and using the recent stock performance as a buying opportunity. Laffer Tengler's Meyers also noted that Alphabet's advantage in personal data, strong user base and dominant market position could give them and edge in AI once they correct their mistakes.
Persons: giant's, Jamie Meyers, It's, They're, Alphabet's, Gene Munster, OpenAI, Dan Hanson, Neuberger Berman, They've, Michael Sansoterra, they're, Hanna Howard, Brad Gerstner, CNBC's, Laffer Tengler's Meyers, Deepwater's Munster Organizations: Microsoft, Meta, Nvidia, Investments, Google, Investors, Silvant Locations: Munster
Semiconductor stocks are off to another hot start to the year. The VanEck Semiconductor ETF (SMH) is up 28.5% in the first three months of 2024. That puts the SMH on pace for its biggest quarterly gain since the first quarter of 2023, when it jumped 30%. The stock is up more than 30% to start 2024. Shares have skyrocketed more than 39% to start 2024, helped by strong sales in high bandwidth memory necessary in AI infrastructure.
Persons: Ken Mahoney, Nvidia, Hendi, Management's Paul Meeks, Andrew Garthwaite cautioning Organizations: VanEck Semiconductor, Asset, Taiwan Semiconductor Manufacturing, Nvidia, Qualcomm, Apple, Devices, JPMorgan, PHLX Semiconductor, Intel, Micron Technology, Micron, UBS, Universal Locations: Taiwan
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNvidia is experiencing a once in a generation tech advancement, says Gabelli's Howard WardHoward Ward, Gabelli Funds CIO of growth, joins 'Closing Bell: Overtime' to offer his big tech playbook and finding growth opportunities in the sector.
Persons: Gabelli's Howard Ward Howard Ward Organizations: Nvidia
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTwo investors debate the outlook for Boeing amid leadership shake-upTony Bancroft, Portfolio Manager at Gabelli Funds, and Nancy Tengler, CEO and CIO of Laffer Tengler Investments, debate the path ahead for Boeing as it undergoes significant C-suite changes.
Persons: Tony Bancroft, Nancy Tengler Organizations: Boeing, Funds, Laffer, Investments
Boeing C-suite shakeup: Here's what you need to know
  + stars: | 2024-03-25 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBoeing C-suite shakeup: Here's what you need to knowTony Bancroft, portfolio manager at Gabelli Funds, and Ron Epstein, Bank of America Securities senior aerospace analyst, join 'The Exchange' to discuss recent developments in Boeing's leadership, including the coming departure of CEO Dave Calhoun, the outlook for Boeing's stock, and more.
Persons: Tony Bancroft, Ron Epstein, Dave Calhoun Organizations: Boeing, Gabelli Funds, Bank of America Securities
GE stock has been on a tear, outperforming the market over the past year, as investors bet that the company's break-up will unlock still more value. Since the health-care spinoff, GE shares have risen above $170 from the $60s. He expects anyone buying GE Vernova shares in April will get "a 50% move over the next fourteen months." GE's aerospace business benefits from a dominant market position where it leads in both widebody and narrowbody jet engines. Still, GE Vernova was a weak spot for the company since 2015, according to analysts.
Persons: haven't, FactSet, Gordon Haskett, Don Bilson, GE's, Andrew Obin, Obin, I've, Tony Bancroft, Scott Deuschle, Deuschle, Bancroft, Larry Culp, Culp, GE Vernova, Michael Bloom Organizations: GE Vernova, New York Stock Exchange, GE, GE Healthcare Technologies, General Electric, GE Healthcare, Bank of America, GE Aerospace, Gabelli, Aerospace & Defense ETF, Deutsche Bank, Bank, America's
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailIf there was a serious issue, the FAA would have shut down Boeing: Gabelli Funds' Tony BancroftTony Bancroft, portfolio manager at Gabelli Funds, joins 'The Exchange' to discuss his outlook on Boeing's reputation, safety concerns about traveling on a Boeing aircraft, and more.
Persons: Tony Bancroft Tony Bancroft Organizations: FAA, Boeing, Gabelli
VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.
Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly
The latest concern threatening regional banks started on Jan. 31, when New York Community Bancorp. reported unexpected fourth quarter loss and a large loan loss reserve against futures losses, due in part to the bank's commercial real estate (CRE) exposure. One worry is that the NYCB credit downgrade could spur ratings agencies to take a closer look at other banks, or cause clients to again pull deposits out of regional banks. Determining exactly how unique NYCB's exposure to commercial real estate is will be a key focus for investors and analysts in coming weeks. A note on Wednesday from Wolfe Research analysts focused on banks and commercial real estate showed that regional banks have in general reduced their commercial real estate exposure over the past 15 years.
Persons: NYCB, Ian Lyngen, hasn't, Lyngen, D.A, Davidson, Peter Winter, Winter, Macrae Sykes, Banks, They're, Sykes, Wells Fargo, Jerome Powell, Bond, Tom Fitzpatrick, RJ O'Brien, Fitzpatrick, — CNBC's Michael Bloom Organizations: Investors, New York Community Bancorp, Moody's, Street, Silicon Valley Bank, BMO, Treasury, Wolfe Research, UBS, Gabelli, CNBC Locations: Silicon, Wells
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCVS drug price overhaul 'will likely be phased in over several years', says Gabelli's Jeff JonasJeff Jonas, Gabelli Funds Portfolio Manager, joins 'Closing Bell Overtime' to talk CVS overhauling drug pricing, investing opportunity in the healthcare sector and more.
Persons: Jeff Jonas Jeff Jonas
Indeed, studies show that drinking alcohol is less in vogue with younger millennials and Gen Z. Mounting concern around weight loss drugs GLP-1 drugs, which mimic the action of the glucagon-like peptide-1 hormone and stimulate insulin secretion after a meal, lower blood sugar and send feeling of fullness to the brain. What's more, GLP-1 drugs are an overwhelmingly American topic, with most Europeans unaware of them or unwilling to pay high prices. In total, GLP-1 users are only a very small slice of total alcohol consumers, said Spiros Malandrakis, lead alcohol industry researcher at Euromonitor International. The most vulnerable purveyors are those that are trailing the shift in consumption, notably domestic, non-premium beer brands.
Persons: Katie Pell, Pell, wasn't, millennials, Eli Lilly's Mounjaro, Goldman Sachs, Jason English, Nadine Sarwat, Bernstein, Sarwat, Spiros Malandrakis, , BUD YTD, who'd, Mickey Velado, Brian Sudano, Nell Healy, Healy, she's, Malandrakis, Ryan Brigden, Brigden, Sudano, Joseph Gabelli, Gabelli, Z, there's, it's, Garrett Nelson, They've, seltzer, Nelson, Molson Coors, Bud, he's Organizations: Gallup, Drugs, Nordisk's Ozempic, JPMorgan, CNBC, Euromonitor, Anheuser, Busch Inbev, Beverage Marketing, Constellation, Guinness, Corona, Heineken, Athletic Brewing Company, Heineken Holding, Carlsberg, Constellation Brands, Malandrakis, Beverage, Gabelli, Diageo, Molson Coors, Busch InBev, Molson, Anheuser Busch Locations: Brooklyn, U.S, GLP, imbibing, Angeles, Colorado, Washington, California, North Carolina, San Francisco Bay, Europe, British, Brazil, India
"In a different cycle, when inflation hadn't spiked so much, I think the Fed would have been cutting rates already. "If the real fed funds rate continues to go higher as I expect it will, then you'd want to offset that through rate cuts. And the amount of rate cuts I think they're going to have to do is a relatively large amount." "I think there's a real risk of a hard landing if the Fed doesn't start cutting rates pretty soon," the head of Pershing Square Capital Management added. However, even some of the historically more dovish Fed officials aren't showing their hands on when they think cuts will come.
Persons: Valerie Plesch, Kathy Jones, Charles Schwab, Christopher Waller, Michelle Bowman, Waller, Bowman, Joseph LaVorgna, Donald Trump, Chris Marangi, Bill Ackman, Ackman, David Rubenstein, Raphael Bostic, Thomas Barkin Organizations: Eccles Federal, Bloomberg, Getty, Federal Reserve, Fed, Nikko Securities America, National Economic Council, CME Group, Stocks, Gabelli, Market, Pershing, Capital Management, Atlanta Federal Reserve, Richmond Locations: Washington , DC, Atlanta
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe're in for a 'softish' landing in 2024, says Gabelli Funds' Chris MarangiChris Marangi, Gabelli Funds co-CIO of value, joins 'The Exchange' to discuss the likelihood of a Santa Claus rally, investment opportunities in the market, his recession outlook and more.
Persons: Chris Marangi Chris Marangi Locations: Santa
Analysts attended earnings calls in the third quarter armed with questions for healthcare and consumer companies about the potential effect on their sales from the growing popularity of these drugs, known as GLP-1 agonists. A Reuters analysis of earnings transcripts for the third quarter showed "GLP-1" or alternatives like "obesity" or "weight-loss medications" were mentioned 256 times across 29 U.S. and European healthcare and consumer companies. That's more than double the mentions for the second quarter, when those phrases came up 127 times. While some consumer companies have talked about factors such as fewer calories being consumed, "these kind of large extrapolations" seem to be a bit of a stretch, said BMO Capital analyst Evan Seigerman. For big pharma manufacturers like Pfizer (PFE.N) and Amgen (AMGN.O), analyst questions were aimed at their obesity drug candidates.
Persons: Lilly, George Frey, Jeff Jonas, it's, Eli Lilly's, John Furner, Mondelez, Eli Lilly, Evan Seigerman, LVMH, Rajesh Kumar, Jonas, Bhanvi Satija, Savyata Mishra, Arpan Varghese, David Gaffen, Shounak Organizations: Novo Nordisk, Pharmacy, REUTERS, Gabelli, Novo, Walmart, Walmart U.S, Hershey, Truist Securities, Krispy, BMO Capital, Danish, pharma, Pfizer, Devices, HSBC, Thomson Locations: Provo , Utah, U.S, United States, Novo, Bengaluru
Such forecasts have prompted a sell-off in a wide range of companies from makers of bariatric surgery devices to companies whose products address the health issues created by excess weight, from diabetes to sleep apnea. "The market is in a shoot-first, ask-questions-later mood when it comes to weight-loss drugs," said Nicholas Anderson, manager of the Thornburg International Growth Fund, which holds shares of Novo Nordisk. By contrast, the iShares U.S. Medical Devices exchange-traded fund has lost more than 22% in the last three months. Injectable weight-loss drugs, known as GLP-1 receptor agonists, are considered highly effective but are also expensive, costing more than $1,300 per month. "Overall, we'll see an increased interest in bariatric surgery, but that will get delayed in the short term."
Persons: Doctor Thomas Horbach, Wegovy, Nicholas Anderson, Eli Lilly, Kenneth Stein, Margaret Kaczor Andrew, William Blair, Michael Farrell, Jeff Jonas, Johnson, Myriam Curet, Ann Hynes, Hynes, David Gaffen, Manas, Michael Erman, Caroline Humer, Sonali Paul Organizations: Novo Nordisk, Healthcare, Growth Fund, Medical Devices, Boston, Gabelli Funds, Johnson, Reuters, Mizuho Securities, Manas Mishra, Thomson Locations: Germany, Munich, Danish, U.S, Boston, GLP, New York, Bengaluru
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGabelli Funds' Kevin Dreyer offers his 'underfollowed and unloved' stock picksKevin Dreyer, Gabelli Funds co-CIO, joins 'Closing Bell' to discuss opportunity plays outside of mega-cap tech.
Persons: Kevin Dreyer Organizations: Gabelli
One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. "This is a major shortcoming in terms of not just quality of life for the patients who have to lose lean muscle mass, but there's actually room to improve on the weight loss and there [are] other metabolic benefits to improving your lean muscle mass ... [including] you might have better durability of weight loss." The drug is being tested in a phase 2b study alongside semaglutide to protect against loss of muscle mass. Until then, patients will need to watch what they eat and focus on exercise just as they would on any other weight loss regimen. When that occurs, muscle loss will be an even bigger issue than it is now.
Persons: Piper Sandler, Allison Bratzel, there's, Bratzel, Versanis, Eli Lilly, Eli Lilly's Mounjaro, they're, Lydia Alexander, Alexander, Sandler's Bratzel, incretins, Biohaven, Nestle, Ulf Mark Schneider, Jeff Jonas, Jonas, Stephens, Jim Salera, Atkins, Morgan Stanley, — CNBC's Michael Bloom Organizations: Wall, Nordisk's Ozempic, Obesity Medicine Association, Bristol Myers Squibb, Nestle, Gabelli, Quest, Foods Locations: Swiss
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGabelli Funds' Chris Marangi on why he's investing in consumer-facing stocksChris Marangi, Co-CIO of Value at Gabelli Funds, discusses how he's investing in the markets.
Persons: Chris Marangi Organizations: Funds
“They tend to close in these neighborhoods regardless of whether or not there is another pharmacy nearby,” Qato said. Closings can create so-called “pharmacy deserts,” or neighborhoods without easy access to a drugstore. “It’ll kind of worsen the problem of pharmacy deserts and disparities in pharmacy access,” Qato said. She noted that patients who lose drugstore access are less likely to stay on their regular prescriptions, and that can affect their health. Jonas said drugstores do want to help with pharmacy access, but the economics still need to work for these companies.
Persons: Dima Qato, ” Qato, Jeff Jonas, Jonas, drugstores, , Ted Shaffrey Organizations: East, Street, University of Southern, Gabelli Funds, Rite Aid, Associated Press, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: West, University of Southern California, Philadelphia, Virginia
At the same time, legacy media companies face off against another well-known demon: cord-cutting. Technology companies such as Apple and Amazon can lean on their respective hardware and e-commerce businesses, said Paul Fanelli, a research analyst at Gabelli Funds. Even so, Wall Street sees only a handful of pure-play winners in the TV and streaming space winning consumer attention over the long run. Already, the technology companies have shown some promise. Consumers are increasingly forgoing pay TV packages from cable companies and opting for bundles from companies like Alphabet, he said.
Persons: Rosenblatt, Barton Crockett, It's, Netflix's, Ken Leon, Hollywood's, Leon, Jamie Lumley, Paul Fanelli, it's, Apple's, Amazon's, That's, Needham, Laura Martin, Martin, , John Hodulik, CNBC's, bode, Crockett, NBCUniversal's Peacock, Brandon Nispel, Nispel, Disney's hasn't, Fanelli, that's Organizations: Netflix, Apple, Paramount, Sky, Third, Gabelli, Warner, UBS, ESPN, Fox, NFL, Hulu, YouTube, KeyBanc, Comcast, Disney, Warner Bros, Max, DIS, Rosenblatt, ABC, Nexstar, CNBC Locations: France, United Kingdom
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThere's a definite cost advantage for Tesla using non-union plants, says Gabelli's Brian SponheimerBrian Sponheimer, Gabelli Funds Portfolio Manager, joins 'Closing Bell Overtime' to talk the impact of the UAW strike on auto stocks, where Tesla gets an advantage and more.
Persons: Brian Sponheimer Brian Sponheimer, Tesla Organizations: UAW
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMarangi: Invest in sectors where companies can create competitive moatsChris Marangi, Co-CIO of Value at Gabelli Funds, discusses where he's investing in the markets.
Persons: Chris Marangi Organizations: Funds Locations: Invest
Total: 25